SubcutaneousActive immunisation against yellow feverAdult: Primary immunisation: 0.5 mL as a single dose, given at least 10 days before entering an endemic area or before potential exposure to yellow fever virus. Booster dose may be given ≥10 years after the last dose for those who are at increased risk of the disease due to location and duration of travel in endemic areas or due to more consistent exposure to virulent virus. Recommendations may vary among countries (refer to latest local guidelines).
Child: ≥9 months Same as adult dose. Recommendations on age-appropriate vaccination may vary among countries (refer to latest local guidelines).
|
|
|
Powder and diluent (in pre-filled syringe) for susp for inj: Reconstitute vaccine using only the supplied diluent in pre-filled syringe. Add the diluent slowly into the vial containing the vaccine. Shake the vial to completely dissolve the powder. Preparation instructions may vary between products (refer to specific product guidelines).
|
Hypersensitivity to yellow fever vaccine, eggs or chicken protein. Severely immunosuppressed patient (e.g. HIV infection or AIDS, leukaemia, lymphoma, thymus disease, generalised malignancy, immunosuppression due to drugs or radiation therapy). Moderate or severe febrile or acute illness; history of thymus dysfunction (including myasthenia gravis and thymoma). Patient who has undergone thymectomy for any reason. Children <6 months.
|
Patient with asymptomatic HIV infection with moderate immunosuppression. Vaccination must not be delayed for patients with mild acute illness (with or without fever). Defer blood donation for 2 weeks after immunisation. Use in children aged 6-8 months may be considered under specific circumstances (e.g. travel to an area where exposure is unavoidable, during major outbreaks) and based on available official recommendations (refer to country-specific guidelines). Elderly. Pregnancy and lactation.
|
Significant: Hypersensitivity or anaphylactoid reactions, syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Nausea, abdominal pain; vomiting (particularly in toddlers).
General disorders and administration site conditions: Asthenia, fever, malaise, local inj site reactions (e.g. pain or tenderness, erythema or redness, haematoma, induration, oedema or swelling); irritability, crying (particularly in children).
Metabolism and nutrition disorders: Loss of appetite (particularly in children).
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Headache, dizziness, paraesthesia; drowsiness (particularly in children).
Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria.
Potentially Fatal: Very rarely, vaccine-associated neurotropic disease (may present as encephalitis or neurologic disease with peripheral nervous system involvement [e.g. Guillain-Barre syndrome]); vaccine-associated viscerotropic disease (may present as non-specific multiorgan system failure or symptoms similar to fulminant wild-type yellow fever virus with hepatic failure and internal bleeding).
|
Observe for hypersensitivity reaction and syncope for 15 minutes after administration. Monitor for adverse effects 10 days following vaccination (particularly in elderly).
|
Immunosuppressants may increase the risk of adverse effects and diminish the therapeutic effect of yellow fever vaccine.
|
May result in false-positive laboratory and/or diagnostic tests for other flavivirus-related diseases (e.g. dengue or Japanese encephalitis).
|
Description:
Mechanism of Action: Yellow fever vaccine, a live attenuated vaccine, induces the production of specific neutralising antibodies against yellow fever virus, thus stimulating an active immunity to yellow fever virus infection.
Onset: Seroconversion: 10-14 days.
Duration: ≥30 years (may be life-long).
|
Store between 2-8°C. Do not freeze. Protect from light. Follow standard procedures for the proper disposal of any unused portions or waste material.
|
|
|
J07BL01 - yellow fever, live attenuated ; Belongs to the class of yellow fever viral vaccines.
|
Anon. Yellow Fever Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 19/03/2024. Anon. Yellow Fever Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/03/2024. Buckingham R (ed). Yellow Fever Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/03/2024. Gershman M and Staples JE. CDC Yellow Book 2024: Yellow Fever. Centers for Disease Control and Prevention. https://www.cdc.gov. Accessed 17/04/2024. Joint Formulary Committee. Yellow Fever Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/03/2024. Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics. Stamaril Suspension for Injection data sheet 20 June 2022. Medsafe. http://www.medsafe.govt.nz. Accessed 19/03/2024. Stamaril, Powder and Solvent for Suspension for Injection in Pre-filled Syringe (Sanofi). MHRA. https://products.mhra.gov.uk. Accessed 19/03/2024. Stamaril, Powder and Solvent for Suspension for Injection in Pre-filled Syringe (Sanofi-Aventis [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 19/03/2024. YF-Vax Injection, Powder, Lyophilized, for Suspension (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 19/03/2024.
|
Đăng xuất
Tiếp tục với Google